

REGENERON - Diversified Pipeline can Buffer the Setback

https://marketpublishers.com/r/R416D8F9474EN.html

Date: May 2012 Pages: 6 Price: US\$ 140.00 (Single User License) ID: R416D8F9474EN

Abstracts

Despite the setback in the pipeline – negative recommendation from FDA advisory committee on approval of ARCALYST (R, for prevention of gout flares, PDUFA: July 30, 2012), EYLEA (VEGF Trap-Eye, L in US, partnered with Bayer for Ex-US, wet AMD) remains the key driver for REGN and growth of this franchise should be able to buffer some setbacks in the pipeline. The FDA advisory panel voted 11-0 against approval of the ARCALYST, citing inadequate safety data. REGN's ex-US partner for Eylea, Bayer entered into co-promotion collaboration with Santen pharma for EYLEA in ... For more detail, please read our report, released on May 14, 2012 on REGN, titled "Diversified Pipeline can Buffer the Setback".



Contents

COMPANIES MENTIONED

Regenerion



I would like to order

Product name: REGENERON - Diversified Pipeline can Buffer the Setback Product link: <u>https://marketpublishers.com/r/R416D8F9474EN.html</u>

> Price: US\$ 140.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/R416D8F9474EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970